ID   SK-GT-2
AC   CVCL_2194
SY   SKGT2
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473450
DR   cancercelllines; CVCL_2194
DR   Cell_Model_Passport; SIDM00393
DR   Cosmic-CLP; 1503364
DR   DepMap; ACH-001653
DR   DSMZ; ACC-702
DR   DSMZCellDive; ACC-702
DR   ECACC; 11012008
DR   EGA; EGAS00001000978
DR   GDSC; 1503364
DR   GEO; GSM1670430
DR   IARC_TP53; 4078
DR   PharmacoDB; SKGT2_1388_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54953659
RX   PubMed=7665247;
RX   PubMed=8334620;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Population: Hispanic.
CC   Doubling time: 44 hours (PubMed=8334620); ~48 hours (DSMZ=ACC-702); ~44 hours (ECACC=11012008).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=7665247; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=20.34%; Native American=14.81%; East Asian, North=2.09%; East Asian, South=0%; South Asian=0%; European, North=30.94%; European, South=31.83% (PubMed=30894373).
CC   Derived from site: In situ; Stomach, fundus; UBERON=UBERON_0001160.
ST   Source(s): Cosmic-CLP; DepMap; DSMZ; ECACC
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12,13
ST   D16S539: 11,12
ST   D18S51: 14,15
ST   D19S433: 12
ST   D21S11: 32 (DSMZ)
ST   D21S11: 32.2 (DepMap)
ST   D2S1338: 16,19
ST   D3S1358: 15
ST   D5S818: 10
ST   D7S820: 9,10
ST   D8S1179: 15
ST   FGA: 26
ST   Penta D: 9
ST   Penta E: 15,17
ST   TH01: 8,9
ST   TPOX: 9,12
ST   vWA: 15,18
DI   NCIt; C8398; Gastric fundus carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=7665247; DOI=10.1002/ijc.2910640109;
RA   Nabeya Y., Loganzo F. Jr., Maslak P., Lai L., de Oliveira A.R.,
RA   Schwartz G.K., Blundell M.L., Altorki N.K., Kelsen D.P., Albino A.P.;
RT   "The mutational status of p53 protein in gastric and esophageal
RT   adenocarcinoma cell lines predicts sensitivity to chemotherapeutic
RT   agents.";
RL   Int. J. Cancer 64:37-46(1995).
//
RX   PubMed=8334620; DOI=10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L;
RA   Altorki N.K., Schwartz G.K., Blundell M.L., Davis B.M., Kelsen D.P.,
RA   Albino A.P.;
RT   "Characterization of cell lines established from human gastric-esophageal
RT   adenocarcinomas. Biologic phenotype and invasion potential.";
RL   Cancer 72:649-657(1993).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//